Diligence memo · auto-generated · as of July 2, 2026
Generico, Llc
Generico, Llc looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Generico, Llc operates in Pharmaceuticals, based in ST. LOUIS.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Generico, Llc has raised $4.2M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).
Largest single filing: $3.8M on 2015-07-28.
Most recent recorded round closed around 2015-07-28.
Valuation (modeled)modeled
Provath models Generico, Llc at approximately $143M (range $2.8M–$1.1B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 2.16× the median modeled value of Seed Pharmaceuticals companies in 2013–2015 (51 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 26 months.
Last raise 10.9 yr ago; this sector typically re-raises about every 13 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 8.6× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 39% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 62% of those peers.
Closest niche peers: Assured Pharma, Inc., Wellesley Pharmaceuticals Llc, Aggamin Pharmaceuticals, LLC, Abeona Therapeutics LLC, Arvinas, Inc..
Peoplefiled
5 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.